Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC).